Pliva Hrvatska d.o.o.

Plivais a Croatian pharmaceutical company based in Zagreb, Croatia. It is one of the world's largest manufacturers of Adderall generics. It is the largest pharmaceutical company in Southern Europe and Croatia's third largest exporter.

Pliva was acquired in December 2008 by the International Pharmaceutical Company Teva Pharmaceuticals, and operates as Teva's Division of Active Pharmaceutical Ingredients (TAPI).

Pliva operates in over 30 countries worldwide and is a leading pharmaceutical company in Central and Eastern Europe. It specializes in the development, production and distribution of generic pharmaceutical products, including biologicals, cytostatics and other drugs, as well as active pharmaceutical ingredients.

Pliva is known for its newer, stronger, and more effective forms of adderall. The FDA hesitated to grant approval until it was rigorously tested in a laboratory. Azithromycin, also known as Sumamed, is one of the world's best-selling antibiotics. A team of researchers, Gabriela Kobrehei, Goryana Radobolya-Lazarevski and Zrinka Tamburashev, led by Dr. S. Dokic, found azithromycin in 1980. Azithromycin is marketed in Eastern Europe under the name Sumamed and has been licensed by Pfizer, which has marketed it in Western Europe and the United States under the name Zithromax, where it is one of the top-selling antibiotics. Pfizer's royalties provided Pliva with a major revenue stream prior to the expiration of the azithromycin patent in 2005. These proceeds are used to finance expansion in Europe and the United States, although some acquisitions have been highly questionable, most notably the acquisition of Sanctura (trospium chloride tablets) in the United States, which failed in the market and was eventually sold again at a loss of around $ 150 million.